Skip to main content
REMEVi
ENES
What REMEVi offers

Oral BPC-157: capsules, bioavailability and the 2026 rules

Oral is a listed route, with one extra condition that the published research does not yet meet on its own.

Oral BPC-157 is one of four routes HHS’s October 2026 policy lists, with an extra condition: the compounder must keep documentation that the oral formulation is adequately bioavailable in humans. Published oral data come from rat studies; we found no published human oral results. REMEVi does not currently offer BPC-157 in any form.

BPC-157 is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.

REMEVi does not currently offer BPC-157.

The oral condition in HHS’s 2026 policy

Every compounded BPC-157 product must meet the policy’s conditions: a patient-specific prescription, a state-licensed 503A pharmacy, bulk substance from an FDA-registered facility with a valid CoA, one active ingredient, the required label and MedWatch reporting. For oral products there is one more: the compounder keeps documentation that the formulation is adequately bioavailable in humans.

Bioavailability means how much of a dose reaches the bloodstream. Peptides are often broken down in the gut, so this condition asks for evidence that an oral product delivers BPC-157 in people.

Federal Register notice (Oct 30, 2026) · The 2026 policy, explained

What is published on oral BPC-157: animal vs human

  • Animal: rat studies gave BPC-157 in drinking water (0.16 µg/mL, about 12 mL per rat per day) in ligament and tendon-muscle injury models. A 2018 review from the main research group reports effects in rat models whether BPC-157 was injected, given by mouth or applied locally.
  • Animal pharmacokinetics: a 2022 rat-and-dog study measured intravenous and intramuscular doses, with a half-life under 30 minutes. It reported no oral data.
  • Human: a phase 1 trial of 1 mg oral tablets in an estimated 42 healthy volunteers was registered in 2015 (NCT02637284). Its status is unknown and no results are posted; a 2025 review describes it as cancelled.

So the published record has no human measurement of how much oral BPC-157 is absorbed. That is the gap the policy’s documentation condition points at.

Capsules sold online vs a compounded oral prescription

Capsules marketed online as supplements or labelled for research use are not compounded prescriptions and are outside the 2026 policy. They come with no prescriber, no patient label, no pharmacy answerable for content, and no bioavailability documentation.

A compounded oral prescription has to meet every condition above, including the human-bioavailability documentation kept by the compounder.

Questions to ask about any oral BPC-157 prescription

  • Is it compounded by a state-licensed 503A pharmacy on a prescription in my name?
  • Does the pharmacy hold documentation that this oral formulation is adequately bioavailable in humans?
  • Is the bulk substance from an FDA-registered facility with a valid certificate of analysis?
  • Does the product contain one active ingredient?
  • Does the label say “This is a compounded drug product. Not for resale.”?

Does oral BPC-157 work?

No published human study answers that. Oral BPC-157 has been studied in rats, given in drinking water, and a registered human trial of oral tablets has no posted results. HHS’s 2026 policy requires the compounder to document adequate human bioavailability for any oral product. BPC-157 is not FDA-approved for any use.

Is oral BPC-157 as effective as injections?

Unknown. No published human study compares oral and injected BPC-157, and no human study has established that either form treats any condition. Rat studies used both, at doses that do not convert to people. Under the 2026 policy, oral products also need documentation of adequate human bioavailability.

Sources

  1. HHS — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, notice of availability, 91 FR 68526 (October 30, 2026) (read November 2, 2026)
  2. Foley & Lardner (Holtz, Beaver, Rosen), National Law Review, Oct 30 2026 — Peptides: HHS announces limited enforcement discretion for compounding six peptides (read November 2, 2026)
  3. Nutritional Outlook (Bigica), Nov 2 2026 — HHS peptide compounding policy: supplement industry implications (read November 2, 2026)
  4. Japjec et al., Biomedicines 2021 — Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats (read November 2, 2026)
  5. Cerovecki et al., J Orthop Res 2010 — Pentadecapeptide BPC 157 (PL 14736) in a rat medial collateral ligament model (read November 2, 2026)
  6. Seiwerth et al., Curr Pharm Des 2018 — BPC 157 and Standard Angiogenic Growth Factors (review) (read November 2, 2026)
  7. He et al., Front Pharmacol 2022 — Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs (read November 2, 2026)
  8. ClinicalTrials.gov — NCT02637284, PCO-02 (BPC-157 oral tablets) Phase I safety and pharmacokinetics trial, status unknown (read November 2, 2026)
  9. Józwiak et al., Pharmaceuticals 2025 — Reply to Sikiric et al., comment on “Multifunctionality and Possible Medical Application of the BPC 157 Peptide” (read November 2, 2026)
  10. Vasireddi et al., HSS Journal 2025 — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (read November 2, 2026)

Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·